Analysts forecast that LeMaitre Vascular Inc (NASDAQ:LMAT) will announce earnings of $0.20 per share for the current quarter, Zacks reports. Two analysts have issued estimates for LeMaitre Vascular’s earnings, with the lowest EPS estimate coming in at $0.20 and the highest estimate coming in at $0.21. LeMaitre Vascular reported earnings per share of $0.16 during the same quarter last year, which would suggest a positive year over year growth rate of 25%. The business is scheduled to report its next quarterly earnings results on Wednesday, April 25th.
According to Zacks, analysts expect that LeMaitre Vascular will report full year earnings of $0.98 per share for the current fiscal year, with EPS estimates ranging from $0.97 to $0.98. For the next fiscal year, analysts forecast that the business will post earnings of $1.12 per share, with EPS estimates ranging from $1.10 to $1.14. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for LeMaitre Vascular.
LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Wednesday, February 21st. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.01. LeMaitre Vascular had a net margin of 17.03% and a return on equity of 16.93%. The company had revenue of $26.15 million for the quarter, compared to the consensus estimate of $26.23 million. During the same quarter in the prior year, the firm earned $0.13 earnings per share. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year.
In related news, Chairman George W. Lemaitre sold 45,000 shares of the company’s stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $34.66, for a total transaction of $1,559,700.00. Following the transaction, the chairman now owns 3,225,709 shares of the company’s stock, valued at $111,803,073.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO George W. Lemaitre sold 5,700 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $35.56, for a total transaction of $202,692.00. Following the transaction, the chief executive officer now directly owns 3,259,263 shares in the company, valued at approximately $115,899,392.28. The disclosure for this sale can be found here. Insiders have sold 137,736 shares of company stock worth $4,866,186 in the last three months. Insiders own 23.70% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. lifted its stake in shares of LeMaitre Vascular by 3.8% during the fourth quarter. BlackRock Inc. now owns 2,265,936 shares of the medical instruments supplier’s stock valued at $72,150,000 after buying an additional 82,607 shares during the period. Conestoga Capital Advisors LLC lifted its stake in shares of LeMaitre Vascular by 55.3% during the fourth quarter. Conestoga Capital Advisors LLC now owns 1,327,376 shares of the medical instruments supplier’s stock valued at $42,264,000 after buying an additional 472,732 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of LeMaitre Vascular by 2.8% during the third quarter. Dimensional Fund Advisors LP now owns 995,747 shares of the medical instruments supplier’s stock valued at $37,261,000 after buying an additional 27,515 shares during the period. Thomson Horstmann & Bryant Inc. increased its position in LeMaitre Vascular by 10.6% during the fourth quarter. Thomson Horstmann & Bryant Inc. now owns 356,517 shares of the medical instruments supplier’s stock worth $11,351,000 after purchasing an additional 34,162 shares during the last quarter. Finally, Allianz Asset Management GmbH increased its position in LeMaitre Vascular by 8.2% during the fourth quarter. Allianz Asset Management GmbH now owns 348,087 shares of the medical instruments supplier’s stock worth $11,083,000 after purchasing an additional 26,267 shares during the last quarter. 72.76% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ LMAT traded down $0.16 on Friday, hitting $37.73. The company’s stock had a trading volume of 165,656 shares, compared to its average volume of 131,300. LeMaitre Vascular has a 12-month low of $24.25 and a 12-month high of $39.88. The company has a market capitalization of $731.15, a PE ratio of 43.87, a price-to-earnings-growth ratio of 2.59 and a beta of 0.54.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, April 5th. Investors of record on Thursday, March 22nd were paid a dividend of $0.07 per share. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.06. The ex-dividend date of this dividend was Wednesday, March 21st. This represents a $0.28 annualized dividend and a dividend yield of 0.74%. LeMaitre Vascular’s dividend payout ratio is presently 32.56%.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.